Carisbamate (RWJ-333369) is an orally active neuromodulator that suppresses the development and propagation of epileptiform discharges, confers neuroprotection following epilepticus-like injury in vitro, and demonstrates robust antiepileptic efficacy in genetic models of generalized and nonconvulsive epilepsy, supporting its translational relevance in epilepsy research.

In cultured hippocampal neurons, Carisbamate (200 μM) acutely inhibited spontaneous recurrent epileptiform discharges (SREDs) after 12 hours in over 95% of neurons, with effects maintained for 24 hours [1].

In the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model, intraperitoneal (i.p.) administration of Carisbamate (10, 30, 60 mg/kg) reduced the expression of spike-and-wave discharges (SWD) dose-dependently. The 60 mg/kg dose completely inhibited SWD after 120 minutes. In audiogenic sensitive Wistar AS rats, Carisbamate (20, 30 mg/kg, i.p.) prevented wild running episodes and tonic seizures in all animals. At 10 mg/kg, the latency to tonic seizure was increased by 327% [6].

DMSO: 80 mg/mL (371.01 mM), Sonication is recommended.